Edge Therapeutics’ EG-1962 Data To Be Presented at International Stroke Conference 2017

Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies in the management of acute, life-threatening conditions, today announced that two posters on Edge’s lead product candidate, EG-1962, will be presented at the International Stroke Conference (ISC) 2017 to be held February 22-24, 2017 in Houston, Texas.

This entry was posted in Recent Development News: Q1 - 2017, Recent Developments. Bookmark the permalink.
Read Full Article »